{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T16:10:40Z","timestamp":1779207040073,"version":"3.51.4"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T00:00:00Z","timestamp":1766102400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T00:00:00Z","timestamp":1766102400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"the Jiangxi Province Natural Science Foundation Project","award":["No. 2025BAC240425"],"award-info":[{"award-number":["No. 2025BAC240425"]}]},{"name":"the Project of the Education Department of Jiangxi Province","award":["No. GJJ2200131"],"award-info":[{"award-number":["No. GJJ2200131"]}]},{"name":"the Science and Technology Project of Traditional Chinese Medicine of Jiangxi Province","award":["No. 2024A0142"],"award-info":[{"award-number":["No. 2024A0142"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"DOI":"10.1007\/s12094-025-04155-x","type":"journal-article","created":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T17:56:20Z","timestamp":1766166980000},"page":"2183-2197","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Silencing of MAT2A inhibits gastric cancer cell proliferation, migration, and invasion through activation of the p53 pathway"],"prefix":"10.1007","volume":"28","author":[{"given":"Yao","family":"Du","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kong-Xian","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liang-Bo","family":"You","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiang-Nan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun-Fu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhi-Yang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-0509-446X","authenticated-orcid":false,"given":"Shun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,19]]},"reference":[{"issue":"6","key":"4155_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394\u2013424. https:\/\/doi.org\/10.3322\/caac.21492.","journal-title":"CA Cancer J Clin"},{"key":"4155_CR2","doi-asserted-by":"publisher","first-page":"29","DOI":"10.4103\/2311-8571.355010","volume":"9","author":"HJ Wu","year":"2023","unstructured":"Wu HJ, Dai WW, Wang LB, Zhang J, Wang CL. Comprehensive analysis of the molecular mechanism for gastric cancer based on competitive endogenous RNA network. World J Tradit Chin Med. 2023;9:29\u201342. https:\/\/doi.org\/10.4103\/2311-8571.355010.","journal-title":"World J Tradit Chin Med"},{"issue":"1","key":"4155_CR3","doi-asserted-by":"publisher","first-page":"26","DOI":"10.5114\/pg.2018.80001","volume":"14","author":"P Rawla","year":"2019","unstructured":"Rawla P, Barsouk A. Epidemiology of gastric cancer: global trends, risk factors and prevention. Prz Gastroenterol. 2019;14(1):26\u201338. https:\/\/doi.org\/10.5114\/pg.2018.80001. (Epub 2018 Nov 28. PMID: 30944675 PMCID: PMC6444111).","journal-title":"Prz Gastroenterol."},{"issue":"8","key":"4155_CR4","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s11912-019-0820-4","volume":"21","author":"FM Johnston","year":"2019","unstructured":"Johnston FM, Beckman M. Updates on Management of Gastric Cancer. Curr Oncol Rep. 2019;21(8):67. https:\/\/doi.org\/10.1007\/s11912-019-0820-4. (PMID: 31236716).","journal-title":"Curr Oncol Rep"},{"key":"4155_CR5","doi-asserted-by":"publisher","first-page":"4064","DOI":"10.1002\/14651858.CD004064.pub2","volume":"2","author":"AD Wagner","year":"2005","unstructured":"Wagner AD, Grothe W, Behl S, Kleber G, Grothey A, Haerting J, et al. Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev. 2005;2:4064. https:\/\/doi.org\/10.1002\/14651858.CD004064.pub2. (PMID: 15846694).","journal-title":"Cochrane Database Syst Rev."},{"issue":"18","key":"4155_CR6","doi-asserted-by":"publisher","first-page":"2903","DOI":"10.1200\/JCO.2005.05.0245","volume":"24","author":"AD Wagner","year":"2006","unstructured":"Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, Fleig WE. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol. 2006;24(18):2903\u20139. https:\/\/doi.org\/10.1200\/JCO.2005.05.0245. (PMID: 16782930).","journal-title":"J Clin Oncol"},{"issue":"9742","key":"4155_CR7","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","volume":"376","author":"YJ Bang","year":"2010","unstructured":"Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687\u201397. https:\/\/doi.org\/10.1016\/S0140-6736(10)61121-X. (Epub 2010 Aug 19. Erratum in: Lancet. 2010 Oct 16;376(9749):1302. PMID: 20728210).","journal-title":"Lancet."},{"issue":"11","key":"4155_CR8","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1016\/S1470-2045(14)70420-6","volume":"15","author":"H Wilke","year":"2014","unstructured":"Wilke H, Muro K, Van Cutsem E, Oh SC, Bodoky G, Shimada Y, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol. 2014;15(11):1224\u201335. https:\/\/doi.org\/10.1016\/S1470-2045(14)70420-6. (Epub 2014 Sep 17 PMID: 25240821).","journal-title":"Lancet Oncol"},{"key":"4155_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2020.153322","volume":"218","author":"J Xie","year":"2021","unstructured":"Xie J, Fu L, Jin L. Immunotherapy of gastric cancer: past, future perspective and challenges. Pathol Res Pract. 2021;218:153322. https:\/\/doi.org\/10.1016\/j.prp.2020.153322.","journal-title":"Pathol Res Pract"},{"issue":"9","key":"4155_CR10","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1093\/annonc\/mdn169","volume":"19","author":"C Gravalos","year":"2008","unstructured":"Gravalos C, Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol. 2008;19(9):1523\u20139. https:\/\/doi.org\/10.1093\/annonc\/mdn169.","journal-title":"Ann Oncol"},{"issue":"2","key":"4155_CR11","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s10120-014-0360-4","volume":"18","author":"AK Nagatsuma","year":"2015","unstructured":"Nagatsuma AK, Aizawa M, Kuwata T, Doi T, Ohtsu A, Fujii H, et al. Expression profiles of HER2, EGFR, MET and FGFR2 in a large cohort of patients with gastric adenocarcinoma. Gastric Cancer. 2015;18(2):227\u201338. https:\/\/doi.org\/10.1007\/s10120-014-0360-4.","journal-title":"Gastric Cancer"},{"issue":"9","key":"4155_CR12","doi-asserted-by":"publisher","first-page":"901","DOI":"10.2147\/DDDT.S75152.PMID:25733810;PMCID:PMC4338255","volume":"16","author":"Y Qing","year":"2015","unstructured":"Qing Y, Li Q, Ren T, Xia W, Peng Y, Liu GL, et al. Upregulation of PD-L1 and APE1 is associated with tumorigenesis and poor prognosis of gastric cancer. Drug Des Devel Ther. 2015;16(9):901\u20139. https:\/\/doi.org\/10.2147\/DDDT.S75152.PMID:25733810;PMCID:PMC4338255.","journal-title":"Drug Des Devel Ther"},{"issue":"2","key":"4155_CR13","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1007\/s10120-015-0519-7","volume":"19","author":"S Eto","year":"2016","unstructured":"Eto S, Yoshikawa K, Nishi M, Higashijima J, Tokunaga T, Nakao T, et al. Programmed cell death protein 1 expression is an independent prognostic factor in gastric cancer after curative resection. Gastric Cancer. 2016;19(2):466\u201371. https:\/\/doi.org\/10.1007\/s10120-015-0519-7. (Epub 2015 Jul 26 PMID: 26210691).","journal-title":"Gastric Cancer"},{"issue":"7517","key":"4155_CR14","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/nature13480","volume":"513","author":"Cancer Genome Atlas Research Network","year":"2014","unstructured":"Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513(7517):202\u20139. https:\/\/doi.org\/10.1038\/nature13480. (Epub 2014 Jul 23 PMID 25079317 PMCID PMC4170219).","journal-title":"Nature."},{"issue":"2","key":"4155_CR15","doi-asserted-by":"publisher","first-page":"93","DOI":"10.3322\/caac.21388","volume":"67","author":"MB Amin","year":"2017","unstructured":"Amin MB, Greene FL, Edge SB, Compton CC, Gershenwald JE, Brookland RK, et al. The eighth edition AJCC cancer staging manual: continuing to build a bridge from a population-based to a more \u201cpersonalized\u201d approach to cancer staging. CA Cancer J Clin. 2017;67(2):93\u20139. https:\/\/doi.org\/10.3322\/caac.21388.","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"4155_CR16","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.cgh.2019.07.045","volume":"18","author":"AP Thrift","year":"2020","unstructured":"Thrift AP, El-Serag HB. Burden of gastric cancer. Clin Gastroenterol Hepatol. 2020;18(3):534\u201342. https:\/\/doi.org\/10.1016\/j.cgh.2019.07.045. (Epub 2019 Jul 27 PMID 31362118 PMCID PMC8859863).","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"1","key":"4155_CR17","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/S0021-9258(18)66148-4","volume":"204","author":"GL Cantoni","year":"1953","unstructured":"Cantoni GL. S-adenosylmethionine; a new intermediate formed enzymatically from L-methionine and adenosinetriphosphate. J Biol Chem. 1953;204(1):403\u201316.","journal-title":"J Biol Chem"},{"issue":"14","key":"4155_CR18","doi-asserted-by":"publisher","first-page":"9531","DOI":"10.1021\/acs.jmedchem.2c00395","volume":"65","author":"C Li","year":"2022","unstructured":"Li C, Gui G, Zhang L, Qin A, Zhou C, Zha X. Overview of Methionine Adenosyltransferase 2A (MAT2A) as an Anticancer Target: Structure, Function, and Inhibitors. J Med Chem. 2022;65(14):9531\u201347. https:\/\/doi.org\/10.1021\/acs.jmedchem.2c00395. (Epub 2022 Jul 7 PMID: 35796517).","journal-title":"J Med Chem"},{"issue":"5","key":"4155_CR19","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/0955-2863(90)90070-2","volume":"1","author":"JD Finkelstein","year":"1990","unstructured":"Finkelstein JD. Methionine metabolism in mammals. J Nutr Biochem. 1990;1(5):228\u201337. https:\/\/doi.org\/10.1016\/0955-2863(90)90070-2. (PMID: 15539209).","journal-title":"J Nutr Biochem"},{"issue":"3","key":"4155_CR20","doi-asserted-by":"publisher","first-page":"409","DOI":"10.3390\/cells11030409.PMID:35159219;PMCID:PMC8834208","volume":"11","author":"RM Pascale","year":"2022","unstructured":"Pascale RM, Simile MM, Calvisi DF, Feo CF, Feo F. S-Adenosylmethionine: from the discovery of its inhibition of tumorigenesis to its use as a therapeutic agent. Cells. 2022;11(3):409. https:\/\/doi.org\/10.3390\/cells11030409.PMID:35159219;PMCID:PMC8834208.","journal-title":"Cells"},{"issue":"12","key":"4155_CR21","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.1016\/j.yexcr.2013.04.005","volume":"319","author":"ML Tomasi","year":"2013","unstructured":"Tomasi ML, Ryoo M, Skay A, Tomasi I, Giordano P, Mato JM, et al. Polyamine and methionine adenosyltransferase 2A crosstalk in human colon and liver cancer. Exp Cell Res. 2013;319(12):1902\u201311. https:\/\/doi.org\/10.1016\/j.yexcr.2013.04.005. (Epub 2013 Apr 12 PMID 23588207 PMCID PMC3700574).","journal-title":"Exp Cell Res."},{"issue":"1","key":"4155_CR22","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1053\/j.gastro.2007.03.114","volume":"133","author":"H Chen","year":"2007","unstructured":"Chen H, Xia M, Lin M, Yang H, Kuhlenkamp J, Li T, et al. Role of methionine adenosyltransferase 2A and S-adenosylmethionine in mitogen-induced growth of human colon cancer cells. Gastroenterology. 2007;133(1):207\u201318. https:\/\/doi.org\/10.1053\/j.gastro.2007.03.114.","journal-title":"Gastroenterology"},{"issue":"31","key":"4155_CR23","doi-asserted-by":"publisher","first-page":"4300","DOI":"10.3748\/wjg.v25.i31.4300.PMID:31496615;PMCID:PMC6710175","volume":"25","author":"B Murray","year":"2019","unstructured":"Murray B, Barbier-Torres L, Fan W, Mato JM, Lu SC. Methionine adenosyltransferases in liver cancer. World J Gastroenterol. 2019;25(31):4300\u201319. https:\/\/doi.org\/10.3748\/wjg.v25.i31.4300.PMID:31496615;PMCID:PMC6710175.","journal-title":"World J Gastroenterol"},{"issue":"4","key":"4155_CR24","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1152\/physrev.00047.2011.PMID:23073625;PMCID:PMC3698976","volume":"92","author":"SC Lu","year":"2012","unstructured":"Lu SC, Mato JM. S-adenosylmethionine in liver health, injury, and cancer. Physiol Rev. 2012;92(4):1515\u201342. https:\/\/doi.org\/10.1152\/physrev.00047.2011.PMID:23073625;PMCID:PMC3698976.","journal-title":"Physiol Rev"},{"issue":"5","key":"4155_CR25","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1111\/j.1872-034X.2007.00041.x","volume":"37","author":"Q Liu","year":"2007","unstructured":"Liu Q, Wu K, Zhu Y, He Y, Wu J, Liu Z. Silencing MAT2A gene by RNA interference inhibited cell growth and induced apoptosis in human hepatoma cells. Hepatol Res. 2007;37(5):376\u201388. https:\/\/doi.org\/10.1111\/j.1872-034X.2007.00041.x.","journal-title":"Hepatol Res"},{"issue":"19","key":"4155_CR26","doi-asserted-by":"publisher","first-page":"17168","DOI":"10.1074\/jbc.M110.167783","volume":"286","author":"Q Liu","year":"2011","unstructured":"Liu Q, Chen J, Liu L, Zhang J, Wang D, Ma L, et al. The X protein of hepatitis B virus inhibits apoptosis in hepatoma cells through enhancing the methionine adenosyltransferase 2A gene expression and reducing S-adenosylmethionine production. J Biol Chem. 2011;286(19):17168\u201380. https:\/\/doi.org\/10.1074\/jbc.M110.167783. (Epub 2011 Jan 19 PMID 21247894 PMCID PMC3089560).","journal-title":"J Biol Chem."},{"issue":"2","key":"4155_CR27","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.ccell.2020.12.010","volume":"39","author":"P Kalev","year":"2021","unstructured":"Kalev P, Hyer ML, Gross S, Konteatis Z, Chen CC, Fletcher M, et al. MAT2A inhibition blocks the growth of MTAP-deleted cancer cells by reducing PRMT5-dependent mRNA splicing and inducing DNA damage. Cancer Cell. 2021;39(2):209-224.e11. https:\/\/doi.org\/10.1016\/j.ccell.2020.12.010. (Epub 2021 Jan 14 PMID: 33450196).","journal-title":"Cancer Cell"},{"issue":"5","key":"4155_CR28","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.3390\/cancers12051342.","volume":"12","author":"KA Secker","year":"2020","unstructured":"Secker KA, Bloechl B, Keppeler H, Duerr-Stoerzer S, Schmid H, Schneidawind D, et al. MAT2A as key regulator and therapeutic target in MLLr Leukemogenesis. Cancers (Basel). 2020;12(5):1342. https:\/\/doi.org\/10.3390\/cancers12051342. (PMID:32456310;PMCID:PMC7281730).","journal-title":"Cancers (Basel)"},{"issue":"8","key":"4155_CR29","doi-asserted-by":"publisher","first-page":"4430","DOI":"10.1021\/acs.jmedchem.0c01895","volume":"64","author":"Z Konteatis","year":"2021","unstructured":"Konteatis Z, Travins J, Gross S, Marjon K, Barnett A, Mandley E, et al. Discovery of AG-270, a first-in-class oral MAT2A inhibitor for the treatment of tumors with homozygous\u00a0MTAP\u00a0deletion. J Med Chem. 2021;64(8):4430\u201349. https:\/\/doi.org\/10.1021\/acs.jmedchem.0c01895.","journal-title":"J Med Chem"},{"key":"4155_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2020.153216","volume":"76","author":"M Yu","year":"2020","unstructured":"Yu M, Ren L, Liang F, Zhang Y, Jiang L, Ma W, et al. Effect of epiberberine from Coptis chinensis Franch on inhibition of tumor growth in MKN-45 xenograft mice. Phytomedicine. 2020;76:153216. https:\/\/doi.org\/10.1016\/j.phymed.2020.153216.","journal-title":"Phytomedicine"},{"key":"4155_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2022.103841","volume":"181","author":"MJ L\u00f3pez","year":"2023","unstructured":"L\u00f3pez MJ, Carbajal J, Alfaro AL, Saravia LG, Zanabria D, Araujo JM, et al. Characteristics of gastric cancer around the world. Crit Rev Oncol Hematol. 2023;181:103841. https:\/\/doi.org\/10.1016\/j.critrevonc.2022.103841. (Epub 2022 Oct 11 PMID: 36240980).","journal-title":"Crit Rev Oncol Hematol"},{"issue":"45","key":"4155_CR32","doi-asserted-by":"publisher","first-page":"78851","DOI":"10.18632\/oncotarget.20234.","volume":"8","author":"ML Tomasi","year":"2017","unstructured":"Tomasi ML, Cossu C, Spissu Y, Floris A, Ryoo M, Iglesias-Ara A, et al. S-adenosylmethionine and methylthioadenosine inhibit cancer metastasis by targeting microRNA 34a\/b-methionine adenosyltransferase 2A\/2B axis. Oncotarget. 2017;8(45):78851\u201369. https:\/\/doi.org\/10.18632\/oncotarget.20234. (PMID:29108270;PMCID:PMC5668003).","journal-title":"Oncotarget"},{"key":"4155_CR33","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.freeradbiomed.2022.02.015","volume":"181","author":"M Ma","year":"2022","unstructured":"Ma M, Kong P, Huang Y, Wang J, Liu X, Hu Y, et al. Activation of MAT2A-ACSL3 pathway protects cells from ferroptosis in gastric cancer. Free Radic Biol Med. 2022;181:288\u201399. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2022.02.015.","journal-title":"Free Radic Biol Med"},{"issue":"1","key":"4155_CR34","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.acthis.2012.03.006","volume":"115","author":"T Zhang","year":"2013","unstructured":"Zhang T, Zheng Z, Liu Y, Zhang J, Zhao Y, Liu Y, et al. Overexpression of methionine adenosyltransferase II alpha (MAT2A) in gastric cancer and induction of cell cycle arrest and apoptosis in SGC-7901 cells by shRNA-mediated silencing of MAT2A gene. Acta Histochem. 2013;115(1):48\u201355. https:\/\/doi.org\/10.1016\/j.acthis.2012.03.006. (Epub 2012 Apr 26 PMID: 22542325).","journal-title":"Acta Histochem"},{"issue":"2","key":"4155_CR35","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001364.","volume":"9","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Yang H, Zhao J, Wan P, Hu Y, Lv K, et al. Activation of MAT2A-RIP1 signaling axis reprograms monocytes in gastric cancer. J Immunother Cancer. 2021;9(2):e001364. https:\/\/doi.org\/10.1136\/jitc-2020-001364. (Erratum.In:JImmunotherCancer.2021Apr;9(4):1.doi:10.1136\/jitc-2020-001364corr1.Erratumin:JImmunotherCancer.2021Oct;9(10):e001364corr2.doi:10.1136\/jitc-2020-001364corr2.PMID:33593829;PMCID:PMC7888314).","journal-title":"J Immunother Cancer"},{"issue":"7","key":"4155_CR36","doi-asserted-by":"publisher","first-page":"784","DOI":"10.7150\/ijbs.6.784","volume":"6","author":"J Luo","year":"2010","unstructured":"Luo J, Li YN, Wang F, Zhang WM, Geng X. S-adenosylmethionine inhibits the growth of cancer cells by reversing the hypomethylation status of c-myc and H-ras in human gastric cancer and colon cancer. Int J Biol Sci. 2010;6(7):784\u201395. https:\/\/doi.org\/10.7150\/ijbs.6.784.","journal-title":"Int J Biol Sci"},{"issue":"1","key":"4155_CR37","doi-asserted-by":"publisher","first-page":"80","DOI":"10.2174\/1389450114666140106101412","volume":"15","author":"B Hong","year":"2014","unstructured":"Hong B, van den Heuvel AP, Prabhu VV, Zhang S, El-Deiry WS. Targeting tumor suppressor p53 for cancer therapy: strategies, challenges and opportunities. Curr Drug Targets. 2014;15(1):80\u20139. https:\/\/doi.org\/10.2174\/1389450114666140106101412.","journal-title":"Curr Drug Targets"},{"issue":"8","key":"4155_CR38","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1038\/nm1087","volume":"10","author":"B Vogelstein","year":"2004","unstructured":"Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med. 2004;10(8):789\u201399. https:\/\/doi.org\/10.1038\/nm1087.","journal-title":"Nat Med"},{"issue":"12","key":"4155_CR39","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1517\/14728222.2012.726985","volume":"16","author":"VV Prabhu","year":"2012","unstructured":"Prabhu VV, Allen JE, Hong B, Zhang S, Cheng H, El-Deiry WS. Therapeutic targeting of the p53 pathway in cancer stem cells. Expert Opin Ther Targets. 2012;16(12):1161\u201374. https:\/\/doi.org\/10.1517\/14728222.2012.726985. (Epub 2012 Sep 24 PMID: 22998602; PMCID: PMC3650610).","journal-title":"Expert Opin Ther Targets."},{"issue":"5013","key":"4155_CR40","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1126\/science.2047879","volume":"252","author":"SE Kern","year":"1991","unstructured":"Kern SE, Kinzler KW, Bruskin A, Jarosz D, Friedman P, Prives C, et al. Identification of p53 as a sequence-specific DNA-binding protein. Science. 1991;252(5013):1708\u201311. https:\/\/doi.org\/10.1126\/science.2047879.","journal-title":"Science"},{"issue":"2","key":"4155_CR41","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/0092-8674(95)90412-3","volume":"80","author":"T Miyashita","year":"1995","unstructured":"Miyashita T, Reed JC. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell. 1995;80(2):293\u20139. https:\/\/doi.org\/10.1016\/0092-8674(95)90412-3.","journal-title":"Cell"},{"issue":"24","key":"4155_CR42","doi-asserted-by":"publisher","first-page":"4661","DOI":"10.4161\/cc.22917","volume":"11","author":"M Quaas","year":"2012","unstructured":"Quaas M, M\u00fcller GA, Engeland K. p53 can repress transcription of cell cycle genes through a p21(WAF1\/CIP1)-dependent switch from MMB to DREAM protein complex binding at CHR promoter elements. Cell Cycle. 2012;11(24):4661\u201372. https:\/\/doi.org\/10.4161\/cc.22917. (Epub 2012 Nov 27 PMID: 23187802 PMCID: PMC3562311).","journal-title":"Cell Cycle."},{"issue":"8","key":"4155_CR43","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.3390\/cancers11081178.PMID:31416295;PMCID:PMC6721478","volume":"11","author":"B Shamloo","year":"2019","unstructured":"Shamloo B, Usluer S. p21 in cancer research. Cancers (Basel). 2019;11(8):1178. https:\/\/doi.org\/10.3390\/cancers11081178.PMID:31416295;PMCID:PMC6721478.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"4155_CR44","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1097\/CCO.0b013e32835b639e","volume":"25","author":"NA Warfel","year":"2013","unstructured":"Warfel NA, El-Deiry WS. p21WAF1 and tumourigenesis: 20 years after. Curr Opin Oncol. 2013;25(1):52\u20138. https:\/\/doi.org\/10.1097\/CCO.0b013e32835b639e. (PMID: 23159848).","journal-title":"Curr Opin Oncol"},{"issue":"5","key":"4155_CR45","first-page":"1169","volume":"54","author":"WS El-Deiry","year":"1994","unstructured":"El-Deiry WS, Harper JW, O\u2019Connor PM, Velculescu VE, Canman CE, Jackman J, et al. WAF1\/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res. 1994;54(5):1169\u20137 (PMID: 8118801).","journal-title":"Cancer Res."},{"issue":"1","key":"4155_CR46","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1097\/00001622-199901000-00014","volume":"11","author":"JC Reed","year":"1999","unstructured":"Reed JC. Mechanisms of apoptosis avoidance in cancer. Curr Opin Oncol. 1999;11(1):68\u201375. https:\/\/doi.org\/10.1097\/00001622-199901000-00014. (PMID: 9914881).","journal-title":"Curr Opin Oncol"},{"issue":"11","key":"4155_CR47","doi-asserted-by":"publisher","first-page":"4699","DOI":"10.1016\/j.asjsur.2024.05.121","volume":"47","author":"SC Huang","year":"2024","unstructured":"Huang SC, Chang IY, Chen TC, Lin HC, Tsai CY, Hsu JT, et al. Redefining aberrant P53 expression of gastric cancer and its distinct clinical significance among molecular-histologic subtypes. Asian J Surg. 2024;47(11):4699\u2013705. https:\/\/doi.org\/10.1016\/j.asjsur.2024.05.121. (Epub 2024 Jun 6 PMID: 38845323).","journal-title":"Asian J Surg"},{"issue":"3","key":"4155_CR48","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.70271.","volume":"15","author":"J Zhang","year":"2025","unstructured":"Zhang J, Tian T, Li X, Xu K, Lu Y, Li X, et al. p53 inhibits OTUD5 transcription to promote GPX4 degradation and induce ferroptosis in gastric cancer. Clin Transl Med. 2025;15(3):e70271. https:\/\/doi.org\/10.1002\/ctm2.70271. (PMID:40070026;PMCID:PMC11897053).","journal-title":"Clin Transl Med"},{"issue":"1","key":"4155_CR49","doi-asserted-by":"publisher","first-page":"9339","DOI":"10.1038\/s41598-025-91319-y.","volume":"15","author":"Y Xing","year":"2025","unstructured":"Xing Y, Li G, Li G, Xu J, Zhang T, Li M, et al. MT1H inhibits the growth of gastric cancer by regulating SLC6A19\/TTC39B\/ADM2 and activating p53-dependent autophagy. Sci Rep. 2025;15(1):9339. https:\/\/doi.org\/10.1038\/s41598-025-91319-y. (PMID:40102553;PMCID:PMC11920260).","journal-title":"Sci Rep"},{"issue":"9","key":"4155_CR50","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.3390\/biom14091098.","volume":"14","author":"W Xiao","year":"2024","unstructured":"Xiao W, Huang TE, Zhou J, Wang B, Wang X, Zeng W, et al. Inhibition of MAT2A Impairs Skeletal Muscle Repair Function. Biomolecules. 2024;14(9):1098. https:\/\/doi.org\/10.3390\/biom14091098. (PMID:39334864;PMCID:PMC11430595).","journal-title":"Biomolecules"},{"issue":"1","key":"4155_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2023.105492.","volume":"300","author":"GT Bedard","year":"2024","unstructured":"Bedard GT, Gilaj N, Peregrina K, Brew I, Tosti E, Shaffer K, et al. Combined inhibition of MTAP and MAT2a mimics synthetic lethality in tumor models via PRMT5 inhibition. J Biol Chem. 2024;300(1):105492. https:\/\/doi.org\/10.1016\/j.jbc.2023.105492. (PMID:38000655;PMCID:PMC10770533).","journal-title":"J Biol Chem"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-025-04155-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-025-04155-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-025-04155-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T15:32:12Z","timestamp":1779204732000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-025-04155-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,19]]},"references-count":51,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["4155"],"URL":"https:\/\/doi.org\/10.1007\/s12094-025-04155-x","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,19]]},"assertion":[{"value":"10 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was conducted in accordance with the declaration of Helsinki and approved by the Ethics Committee of the First Affiliated Hospital of Nanchang University (Ethics number: (2023)CDYFYYLK(06\u2013008)).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and informed consent"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}